BioAtla (BCAB) Other Non-Current Assets (2020 - 2026)
BioAtla's (BCAB) quarterly Other Non-Current Assets came in at $163000.0 in Q2 2026, little changed on a YoY basis from $163000.0 in Q2 2025, and little changed quarter-over-quarter from $163000.0 in Q1 2026.
Analysis
BioAtla (BCAB) Other Non-Current Assets (2020 - 2026) Analysis & Trends
BioAtla (BCAB) has reported Other Non-Current Assets for 7 consecutive years, with $163000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non-Current Assets changed 0.0% year-over-year to $163000.0; the trailing twelve-month figure through Jun 2026 stood at $163000.0 (changed 0.0% YoY), and the FY2025 full-year result was $163000.0, changed N/A from the prior year.
- Other Non-Current Assets was little changed at $163000.0 in Q2 2026 per BCAB's latest filing, from $163000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $163000.0 in Q2 2025 and bottomed at $154000.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $157285.7 across 5 years, with a median of $154000.0 in 2022.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets increased 0.65% in 2022, then fell 0.65% in 2023.
- Over 5 years, Other Non-Current Assets stood at $154000.0 in 2022, then changed by 0.0% to $154000.0 in 2023, then changed by 0.0% to $154000.0 in 2024, then advanced by 5.84% to $163000.0 in 2025, then changed by 0.0% to $163000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $163000.0, $163000.0, and $163000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.46 Bn | 192.47 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 179.92 Bn | 176.75 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 131.37 Bn | 123.51 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.86 Bn | 73.87 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 60.29 Bn | 55.10 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 53.76 Bn | 48.62 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.16 Bn | 29.85 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.90 Bn | 30.62 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 29.13 Bn | 29.13 Bn | 1.16 Mn | 29.59 Mn |
| 10 | BioAtla | 2.33 Mn | 2.33 Mn | - | 163,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 163,000.00 |
| Mar 31, 2026 | 163,000.00 |
| Dec 31, 2025 | 163,000.00 |
| Sep 30, 2025 | 163,000.00 |
| Jun 30, 2025 | 163,000.00 |
| Mar 31, 2024 | 154,000.00 |
| Dec 31, 2023 | 154,000.00 |
| Sep 30, 2023 | 154,000.00 |
| Jun 30, 2023 | 154,000.00 |
| Mar 31, 2023 | 154,000.00 |
| Dec 31, 2022 | 154,000.00 |
| Sep 30, 2022 | 154,000.00 |
| Jun 30, 2022 | 155,000.00 |
| Mar 31, 2022 | 154,000.00 |
| Dec 31, 2021 | 154,000.00 |
| Sep 30, 2021 | 154,000.00 |
| Jun 30, 2021 | 154,000.00 |
| Mar 31, 2021 | 154,000.00 |
| Dec 31, 2020 | 154,000.00 |